The Pulmonary Inflammation Company
The mission of RS BioTherapeutics is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation. RS BioTherapeutics’ first investigational compound (RSBT-001) is a first-in-class therapeutic in development as an alternative to corticosteroids for the treatment of respiratory diseases characterized by pulmonary inflammation including COPD, Idiopathic Pulmonary Fibrosis, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. RSBT-001 harnesses the immune modulating power of specific, anti-inflammatory cannabinoids delivered by a proprietary, polarity adaptive transport mechanism and reduces pulmonary inflammation by targeting the inflammatory cascade in the lungs at multiple levels. RS BioTherapeutics is targeting an IND filing for RSBT-001 in early 2025.
Our leadership team is comprised of industry leaders and specialists who are committed to the advancement of our vision and mission.
Meet the individuals on our advisory team.